A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment
1% in subjects ≥2 years of age with mild to moderate AD. The study will also evaluate the
long-term efficacy of difamilast ointment 1%, including durability of response.